Catheter-related Infections

Micrologix, collaborator, further assess MBI 226 regulatory and market options

Published in Blood Weekly, October 23rd, 2003

Micrologix Biotech, Inc., (MGIXF) and Fujisawa Healthcare, Inc., have agreed to extend the review period on their collaboration and license agreement to January 22, 2004 to further evaluate the available options based on analysis of the MBI 226 phase III results.

Pursuant to the collaboration and license agreement dated July 8, 2002, Fujisawa has a right of termination that provides for a 60-day period for termination of the agreement following receipt of the executive summary of the MBI 226 phase III study results.

Prior to this extension, Fujisawa had until September 22, 2003, to make its decision. Fujisawa and Micrologix have agreed to extend this...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry

Search our medical news database